Adaptimmune Therapeutics said Friday it will present pre-clinical data from two T-cell candidates, including data from its wholly-owned MAGE-A4 Specific Peptide Enhanced Affinity Receptor T-cells.
The data will be presented at the 2016 Society for Immunotherapy for Cancer annual meeting and shows that “MAGE-A4 is an attractive target which is broadly expressed in multiple solid tumors,” said Adaptimmune’s chief technology officer Gwendolyn Binder-Scholl.
Binder-Scholl added, “Our MAGE-A4 SPEAR T-cell candidate has shown promising activity without any major safety concerns identified by our extensive preclinical testing.”
Separately, the company said an oral presentation was made with updated data from a study of NY-ESO Spear (Specific Peptide Enhanced Affinity Receptor) T-cells in an ongoing synovial sarcoma trial at the 2016 Connective Tissue Oncology Society meeting in Lisbon, Portugal.
The presentation said that the median survival for cohort 1 is now expected to be about 18 months (80 weeks) compared to about 13 months (56 weeks) as previously reported, and that there continues to be additional partial responses among low NY-ESO expressors in cohort 2, which is currently ongoing.